What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1, Pre-Registered Trial).

December 8, 2025BloodOpen Access

First-in-human randomized placebo-controlled Phase 1 study of RPT1G, a novel hyperbolic NAMPT inhibitor for use in acute leukemias: Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers

View Full Paper

Ask AI

Bookmark

Authors

First-in-human trial shows RPT1G is safe and well-tolerated, demonstrating meaningful NAMPT inhibition in healthy adults.

This trial aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of RPT1G in healthy individuals.
Phase 1, single-center, randomized, double-blind, placebo-controlled trial
Administered RPT1G at single and multiple ascending doses to healthy volunteers
Primary objectives focused on safety, with secondary objectives on pharmacokinetics and pharmacodynamics.
No serious adverse events or treatment emergent adverse events above Grade 2 reported in participants
RPT1G demonstrated favorable pharmacokinetics with a half-life of approximately 6 hours
Significant NAMPT target engagement with increased levels of nicotinamide and 1-methylnicotinamide observed.

Schelle et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

First-in-human trial shows RPT1G is safe and well-tolerated, demonstrating meaningful NAMPT inhibition in healthy adults.

This trial aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of RPT1G in healthy individuals.
Phase 1, single-center, randomized, double-blind, placebo-controlled trial
Administered RPT1G at single and multiple ascending doses to healthy volunteers
Primary objectives focused on safety, with secondary objectives on pharmacokinetics and pharmacodynamics.
No serious adverse events or treatment emergent adverse events above Grade 2 reported in participants
RPT1G demonstrated favorable pharmacokinetics with a half-life of approximately 6 hours
Significant NAMPT target engagement with increased levels of nicotinamide and 1-methylnicotinamide observed.

Schelle et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark